A custom-built skin cancer vaccine is showing major promise in clinical trials, cutting the risk of melanoma returning or proving fatal by 42% when used alongside standard immunotherapy. During the study, two-thirds of participating patients received the experimental shot, which was tailor-made using genetic material drawn directly from their own tumor cells.
According to Melanoma Specialist Dr Pippa Corrie, the technology marks an exciting leap forward for targeted medicine, though its overall long-term impact remains under evaluation. She noted that while the personalized approach is a fabulous next step, the trial serves as an essential proof of principle to demonstrate just how much the vaccine is worth in real-world clinical treatment.
By training a patient’s immune system to pinpoint and attack the specific mutations unique to their tumor, researchers hope this customized approach will mark a major turning point in how doctors treat advanced skin cancers.
–ChannelAfrica–
